Related Experiment Videos
Thrombosis in systemic lupus erythematosus: a French collaborative study.
M A Montes de Oca1, M C Babron, O Blétry
1U155 INSERM, Château de Longchamp, Bois de Boulogne, Paris, France.
Archives of Disease in Childhood
|June 1, 1991
Summary
Pediatric systemic lupus erythematosus (SLE) patients with thrombotic episodes showed a strong association with lupus anticoagulant. This finding is crucial for understanding and managing thrombosis risk in childhood SLE.
Area of Science:
- Pediatric Rheumatology
- Hematology
- Immunology
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting children.
- Thrombotic events are a serious complication in SLE, but their specific associations in pediatric cases require further elucidation.
Purpose of the Study:
- To investigate the incidence and characteristics of thrombotic episodes in a cohort of children diagnosed with SLE.
- To identify clinical and laboratory factors associated with thrombosis in pediatric SLE patients.
Main Methods:
- Retrospective analysis of 120 children with SLE diagnosed before age 16.
- Comparison of patients with and without thrombotic episodes regarding American College of Rheumatology criteria, lupus anticoagulant, direct Coombs test, and vasculitis.
Main Results:
- Nine percent (11/120) of children experienced thrombotic episodes, predominantly venous (14/16), with some arterial involvement.
- Lupus anticoagulant was significantly associated with thrombotic episodes (73% vs. 14%, p<0.001).
- Thrombosis presented as an initial sign in 7 out of 11 affected children.
Conclusions:
- Lupus anticoagulant is a key predictor of thrombotic events in pediatric SLE.
- Early identification of lupus anticoagulant may aid in preventing thrombotic complications in children with SLE.